Blawg Search - Law Blogs, Lawyer Blogs, Legal Blogs Directory & Search Engine

... of the awarded costs. Daiichi owns U.S. Patent No. 5,053,407, which relates to levofloxacin, an antibiotic that Daiichi markets under the trade name Levaquin®. Seeking approval to market a generic version of levofloxacin, Defendants-Appellants Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. filed an Abbreviated New Drug Application (ANDA) with the FDA. In response to Mylan's ANDA filing,...

... No. 4,687,777. The challenges to the '777 patent had been initiated by Defendants-Appellants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., and UDL Laboratories, Inc. (Mylan) on the one hand, and Defendants-Appellants Alphapharm Pty., Inc. and Genpharm, Inc. (Alphapharm) on the other. Seeking approval to market a generic version of the antidiabetic agent, 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione, ...

... Irene M. Keeley. AstraZeneca Pharmaceuticals LP, et al. v. Mylan Laboratories, Inc., Civil Action No. 1:07-CV-00177. In the action, AstraZeneca ... approval for rosuvastatin calcium tablets, which is the generic version of Crestor. According to the complaint, Mylan's position before the FDA is that AstraZeneca's patent for Crestor is invalid and ... litigation, Judge Keeley has denied the motion to dismiss filed by Eliot Disner in Mylan's legal malpractice lawsuit against him. Here is Judge Keeley's ...

... year. The SEC's order is available here. The Perry settlement arose from the failed attempt by Mylan Laboratories, Inc. to acquire King Pharmaceuticals, Inc. in 2004. Perry had a significant ownership stake in King and stood to benefit from the merger, ... was not in Mylan's best interests. Thus, Perry had different, and possibly inconsistent, interests from those of Mylan's other stockholders. The issue of "empty voting" is part of a larger phenomenon identified by Professors Henry Hu and Bernard ...

By Donald Zuhn -- Last week, the Federal Circuit issued an opinion in Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc. In Mylan Laboratories, the Federal Circuit determined that the District Court for the District of New Jersey properly construed claim 1 of U.S. Patent No. 4,513,006, owned by Plaintiff-Appellee Ortho-McNeil...

... (digoxin tablets, USP, all strengths) for oral use. The products are distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label. The voluntary all-lot recall is due ... lawsuits filed on behalf of people injured by the defective Digitek. There are indications, however, that the FDA agrees with Mylan as regards accountability in the regulatory arena. The following is taken from "CDER's Compliance Office Highlights Manufacturer Accountability", ...

... Phil Milford and Susan Decker at Bloomberg: Pfizer Inc., the world's biggest drugmaker, sued rival Mylan Inc. asking a judge to prohibit sales of a generic version of ... .4 billion in revenue last year, $7.7 billion of it in the U.S. Ranbaxy Laboratories Ltd., India's biggest drugmaker and majority owned by Japan's Daiichi ... and plans to enter the market in November 2011. Pfizer already is suing Apotex Inc. and Teva Pharmaceutical Industries Ltd. to prevent them from selling copies of the medicine ...

... 2002, 2003 and the first six months of 2004. On February 27, 2005, Mylan and King announced that they had mutually agreed to terminate the proposed merger ... community. Similarly, notwithstanding the Commission's findings that Perry had structured its acquisition of Mylan shares and its offsetting derivative hedges to avoid notice to the market, the Commission did ... and Carl Icahn's spouse as the persons filing the Schedule 13D. Mylan Laboratories Inc., Schedule 13D, Item 2 (Sept. 7, 2004). (go back ...

... (Levoflaxacin) - US: CAFC: $1,000,000 in translation costs awarded to prevailing party: Ortho-McNeil Pharmaceutical v Mylan (Patently-O) (Patent Docs) (PatLit) (Patent Baristas) General Generic drug delay called 'systemic' problem at TRIPS ... ) - US: CAFC: $1,000,000 in translation costs awarded to prevailing party: Ortho-McNeil Pharmaceutical v Mylan (Patently-O) (Patent Docs) (PatLit) (Patent Baristas) Lexapro (Escitalopram) - Australia: Full Federal Court confirms enantiomers patentable for 20 ...

... fact, he told delegates of the recent CIP Forum in Sweden that "the judgment in the first CAFC decision [LeapFrog Enterprises Inc v Fisher-Price Inc] on obviousness post-KSR had actually been written before the Supreme Court's decision was handed down ... analyses in anticipation of the ruling (See, e.g., Dystar Textilfarben GMBH & Co Deutschland KG v. C.H. Patrick, Co., et al., Alza Corporation v. Mylan Laboratories, Inc., et al., and Ormco Corporation, et al. v. Align Technology, Inc. etc)?